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Abstract 
Background: Serum concentrations of antimullerian hormone (AMH) correlate 
with ovarian response during assisted reproduction treatment (ART) cycles. 
Objective: This retrospective study attempted to evaluate the selection of ovarian 
stimulation protocols based on serum AMH levels in patients and its impact on the 
results of ART. 
Materials and Methods: Based on AMH levels, the patients with tubal factor 
infertility were divided in three groups of normal, low and high AMH levels. 
Oocyte, good embryo number and pregnancy rate in each group were analyzed.  
Results: Using agonist and antagonist protocols, an increase in serum AMH led to 
higher number of oocytes and better quality embryos. At all low, normal and high 
AMH levels, the agonist protocol led to a more significant increase in the number of 
oocytes than the antagonist protocol (p<0.05). The number of high quality embryos 
significantly increased by the agonist protocol than antagonist protocol in women 
with normal AMH levels of 1.3-2.6 ng/ml (p=0.00). Moreover, the results for the 
number of high quality embryos at AMH ˃2.6 ng/ml was in favor of the antagonist 
protocol (p=0.00). The results showed the lowest pregnancy rate at AMH ˂1.3 
ng/ml. At AMH ˃2.6 ng/ml, there was a significant increase in pregnancy rate 
through the antagonist protocol (p=0.04).  
Conclusion: Findings of this study suggested that the ART results are predictable, 
taking into account the AMH levels. The protocol specific to each patient can be 
used given the AMH level in each individual. This is because the results of each 
protocol depend on individual conditions. 
 
 
 
 
 
 
 
 
 
 
 
Keywords: AMH, Ovarian stimulation protocols, Oocyte, Embryo, Pregnancy rate. 
 
Introduction 
 
COH) plays an important role in 
reproductive medicine. That is why the 
selection of an appropriate ovarian 
stimulation strategy can improve the results of 
assisted reproductive techniques. Although 
the two common ovarian stimulation protocols 
(GnRH agonist and GnRH antagonist) exhibit 
similar implantation and pregnancy rates, 
each protocol entails specific characteristics. 
In fact, the agonist protocol leads to higher 
number of oocytes per cycle, whereas the 
antagonist protocol curtails the gonadotropin 
dose, shortening the stimulation period and 
saving the treatment costs, which in turn leads 
to patient comfort (1-4).  
Therefore, a suitable treatment strategy 
should be selected according to the ovarian 
response required for each person by taking 
( 
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the patient’s conditions into account. Anti-
mullerian hormone (AMH) is a predictor of 
ovarian response used to select the agonist 
and antagonist protocols. This can maximize 
the success rate of assisted reproductive 
techniques, while enhancing the safety of 
ovarian stimulation practices (5). AMH is a 
subcategory of TGFβ produced by the 
granulosa cells of pre-antral and antral 
follicles (6). AMH can prevent the growth and 
recruitment of primordial follicles by reducing 
the sensitivity of follicles to FSH (7). The direct 
relationship between serum AMH levels and 
the number of antral follicles has been 
demonstrated (8).  
Furthermore, the AMH levels do not 
fluctuate during the menstrual cycle (9, 10). 
AMH is considered as an indicator that can be 
employed as the best option during assisted 
reproductive treatment (11). There are very 
few studies on the application of AMH to 
predict the quality of oocytes and embryos 
(12). Based on the AMH level in each patient, 
the COH can improve the clinical pregnancy 
rate and minimize the harm associated with 
ovarian response (13). According to previous 
studies, different results have been obtained 
by using agonist and antagonist protocols in 
normal, low and high AMH levels (14). The 
COH may give rise to certain problems due to 
different ovarian responses to FSH (15).  
This extensive study intended to compare 
the number of oocytes, quality of embryo and 
ultimately pregnancy rate through the agonist 
and antagonist protocols in patients with 
different AMH levels. There have been no 
studies so far comparing the results of both 
protocols in normal, low and high responders 
based on serum AMH levels. 
 
Materials and methods 
 
This retrospective study was conducted on 
243 patients under ICSI treatment in the 
private assisted reproduction (Laleh Hospital) 
ICSI during 2012-2014. 
 
Characteristics 
The patients included women with tubal 
factor infertility at age less than 40 years, 
normal menstrual cycle, presence of two 
ovaries, with no history of ovarian surgery, 
chemotherapy, endocrine disorders and 
hormonal therapy. The preliminary analysis 
involved infertility details, medical history, past 
surgeries and obstetric examinations one 
month prior to the treatment. Furthermore, the 
trans-vaginal ultrasonography was performed 
to assess the local pathology and hormonal 
profile, including FSH, TSH and serum AMH 
levels in 2-3 days of menstrual cycle.  
 
Ovarian stimulation protocols 
According to clinical diagnosis, the patients 
underwent ovarian stimulation through GnRH 
agonist and antagonist protocols. The GnRH 
agonist protocol involved daily subcutaneous 
injection of 0.1 mg triptorelin acetat 
(decapeptyl, Ferring Pharmaceuticals, 
Netherlands) in the mid-luteal phase (day 20) 
and menstrual cycle before the stimulation. 
The ovarian stimulation was obtained from 
day 2 or 3 of the cycle by subcutaneous 
injection of recombinant human FSH (Gonal-
F, Merk Serono, Germany) at a fixed dose of 
150-225 IU and then continued by injection of 
hCG.  
The ovarian response was monitored 
through serial ultrasonography and evaluation 
of serum estradiol levels. GnRH antagonist 
protocol performed by administration of 
gonadotropin rFSH on day 2 of the cycle 
along with GnRH antagonist cetrorelix 
(Cetrotide, ASTA Medica, Amsterdam, The 
Netherlands; 0.25 mg/d, s.c) on day 9 post-
stimulation. In all patients, the ovulation 
stimulation was done with 5000-10000 units of 
hCG, leading to a follicle diameter of 19 mm 
and a desirable level of serum estradiol. The 
oocytes were retrieved through transvaginal 
ultrasound-guided technique 36 hours after 
administration of hCG.  
The intracytoplasmic sperm injection was 
performed following the oocyte retrieval and 
oocytes denudation. The incidence of 
fertilization was assessed 19-21 hr after the 
injection in the presence of two pronuclei. The 
quality of embryo was recorded based on the 
number of blastomeres and percentage of 
fragmentation 42-44 hr after the injection, 
which was then comparatively studied. This 
study attempted to compare the number of 
high quality embryos characterized by (i) 4 or 
5 blastomeres on the 2 PndP and minimum 7 
blastomeres on the 3PrdP day after fertilization, 
(ii) absence of multi-nucleotide blastomeres, 
and (iii) fragmentation of less than 20% on 2 Pnd P 
and 3PrdP days after fertilization.  
During the assessment of results, the 
patients were divided on the basis of serum 
AMH and ovarian stimulation protocols 
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AMH into three groups: 1) AMH ˂1.3 ng/ml, 2) 
AMH between 1.3-2.6 ng/ml and 3) AMH ˃2.6 
ng/ml (14). This study exclusively compared 
the number of oocytes, high quality embryos 
and pregnancy rates using two different 
protocols at three AMH levels. 
 
Statistical analysis 
SPSS software (SPSS, version 21 for 
windows; SPSS Inc., Chicago. IL), ANOVA 
including Tukey internal test was used to 
compare quantitative variables between the 
groups and χP2Pfor qualitative variables. p˂0.05 
was considered statistically significant. 
 
Results 
 
The data on age and hormonal profiles 
have been listed in table I, where there are no 
significant differences between the two 
protocols in these three groups. The results 
indicated that the number of oocytes was 
significantly higher when using the agonist 
protocol in women with AMH of 1.3-2.6 ng/ml 
compared to the antagonist protocol 
(10.16±0.27 vs. 9.01±0.3, p=0.006) (Figure 1). 
The number of high quality embryos showed a 
dramatic increase by the agonist protocol than 
the antagonist protocol (6.23±0.2 vs. 
3.88±0.17, p=0.00) (Figure 2). Despite the 
difference in the two protocols in the numbers 
of oocytes and high quality embryos, the 
pregnancy rates did not show any significant 
difference. Nonetheless, the pregnancy rate 
was higher in the agonist protocol than the 
antagonist protocol (52% and 43%, 
respectively) (Figure 3).  
In women with low AMH levels (˂1.3 
ng/ml), the number of oocytes obtained by the 
agonist protocol was significantly higher than 
that by the antagonist protocol (2.23±0.11 vs. 
˂2, p˂0.001) (Figure 1). Nevertheless, there 
was no significant difference between the 
agonist protocol (0.88±0.08) and the 
antagonist protocol (0.78±0.07) in the number 
of high quality embryos, p=0.34 (Figure 2). 
Although the number of oocytes and high 
quality embryos is in favor of the agonist 
protocol, the pregnancy rate in the antagonist 
protocol is higher than in the agonist protocol, 
indicating an insignificant difference (15% vs. 
11%, respectively) (Figure 3). 
In women with high ovarian response 
(AMH ˃2.6 ng/ml), there was a high number of 
oocytes obtained by agonist protocol, 
indicating a significant increase compared to 
antagonist protocol (22.26±0.64 vs. 
18.41±0.55, p=0.00) (Figure 1). The 
comparison of the number of embryos showed 
different patterns. In fact, the number of high 
quality embryos was significantly higher when 
using the antagonist protocol, compared to the 
agonist protocol (9±0.32 vs. 7.71±0.26, 
p=0.002) (Figure 2). Similar to the number of 
high quality embryos, the pregnancy rate 
significantly increased when using the 
antagonist protocol, compared to the agonist 
protocol (61% vs. 47%, respectively) (Figure 
3). 
The comparison of AMH levels against the 
results of ovarian stimulation, quality of 
embryo and pregnancy rate demonstrated that 
an increase in AMH level significantly 
increased the number of oocytes and good 
quality embryos when using both protocols. In 
fact, the highest number of oocytes and high 
quality embryos in both protocols were 
observed at the highest AMH level, whereas, 
the lowest AMH level was associated with the 
lowest number of oocytes and embryos. The 
pregnancy rate patterns varied in different 
AMH levels in these two protocols. In fact, the 
highest pregnancy rate at normal AMH level 
was observed in agonist protocol, even 
though the difference was insignificant in 
comparison of high AMH level.  
The comparison of the normal and high 
AMH level groups, however, showed a 
significant increase in comparison of the 
lowest AMH level. In the antagonist protocol, 
the highest pregnancy rate was observed at 
the highest AMH level, indicating a 
significantly higher increase than the other two 
groups of AMH (1.3-2.6 and ˂1.3). Moreover, 
the pregnancy rate at normal AMH level 
increased significantly higher than the lowest 
level (˂1.3 ng/ml). In total, the levels of serum 
AMH in all patients undergoing antagonist 
protocol stimulation showed a positive 
correlation with the number of retrieved 
oocytes (r=0.82, p<0.01), embryo count 
(r=0.66, p<0.01) and pregnancy (r=0.32, 
p<0.01) (Figure 4). Also, the levels of AMH in 
patients who received agonist protocol 
showed a positive correlation with the number 
of retrieved oocytes (r=0.86, p<0.01), embryo 
count (r=0.68, p<0.01) and pregnancy (r=0.36, 
p<0.01) (Figure 1). Furthermore, according to 
the stimulation protocols used, AMH also was 
an accurate marker of pregnancy in both 
agonist and antagonist protocol (AUC of 0.69 
and 0.72, respectively) (Figure 5, 6). 
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Table I. Mean (standard deviation) age, number of oocytes retrieved, embryo number, FSH, TSH levels in the GnRH-a long protocol 
vs. GnRH-ant protocol group 
Variables GnRH-a long protocol (n = 123) 
GnRH-ant protocol 
(n = 120) p-value 
Age  36 ± 4.07 37 ± 3.6 0.11 
Serum FSH (IU/L)    
 AMH <1.3 (ng/ml) 9.1 ± 0.45 (41) 8.58 ± 0.64 (39) 0.26 
 AMH 1.3-2.6 6.65 ± 0.9 (42) 6.9 ± 0.61 (40) 0.33 
 AMH>2.6 7.27 ± 0.71 (40) 7.61 ± 0.82 (41) 0.39 
Serum TSH (IU/L)    
 AMH<1.3 (ng/ml) 2.66 ± 1.01 2.91 ± 0.98 0.79 
 AMH 1.3-2.6 2.2 ± 0.34 2.67 ± 0.56 0.10 
 AMH>2.6 2.83 ± 0.58 2.39 ± 0.43 0.68 
BMI (kg/m2)    
 AMH<1.3 (ng/ml) 24 ± 1.5 23 ± 1.2 0.14 
 AMH 1.3-2.6 22 ± 1.1 22 ± 1.17 0.81 
 AMH>2.6 21 ± 1.2 22 ± 1.4 0.43 
FSH: follicle-stimulating hormone  TSH: thyroid-stimulating hormone 
AMH: anti-mullerian hormone   BMI: body mass index 
 
 
 
 
 
0
5
10
15
20
25
AMH˂1.3 AMH 1.3-2.6 AMH˃2.6
O
oc
yt
e 
nu
m
be
r
GnRH agonist GnRH antagonist
*
*
*
a
b
c
d
e
f
 
Figure 1. Oocyte retrieval in three AMH levels with GnRH agonist protocol vs antagonist protocol. *shows statistical difference 
between two protocols (p˂0.05). The letter shows statistical difference within and between groups (p˂0.05) 
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Figure 2. High embryo quality in three AMH levels with GnRH agonist protocol vs antagonist protocol. *shows statistical difference 
between two protocols (p˂0.05). The letter shows statistical difference within and between groups (p˂0.05) 
 
 
AMH and ovarian stimulation protocols 
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Figure 3. Pregnancy percentage in three AMH levels with GnRH agonist protocol vs antagonist protocol. *shows statistical 
difference between two protocols (p˂0.05). The letter shows statistical difference within and between groups (P˂ 0.05) 
 
 
 
 
Figure 4. Correlations between AMH level, oocyte and embryo with positive pregnancy in both antagonist and agonist protocol. 
 
 
Figure 5. Comparison of predictive values for positive 
pregnancy using the ROC curve analysis in antagonist 
protocol 
 
Figure 6. Comparison of predictive values for positive 
pregnancy using the ROC curve analysis in agonist protocol 
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Discussion 
 
In this study, the results of GnRH agonist 
and GnRH antagonist protocols were explored 
based on serum AMH levels. It was proven 
that an increase in serum AMH level led to a 
higher number of oocytes and embryos. 
These results were consistent with the 
findings of other studies. The serum AMH 
level can be adopted as a predictor of ovarian 
response in ART cycles (5, 16). Ovarian 
response is an important success factor in 
ART results. The two common protocols of 
ovarian stimulation are associated with 
different ovarian responses, each entailing a 
unique characteristic (17).  
Just as demonstrated in this study, the use 
of two different protocols in women with low 
serum AMH levels led to different ovarian 
responses. In this regard, some studies 
preferred the GnRH agonist, whereas others 
the GnRH protocol for patients with low AMH 
levels or a history of weak ovarian response 
(18, 19).  
According to the current study, although 
the GnRH agonist yielded a greater number of 
oocytes, it did not increase the number of high 
quality embryos compared to the GnRH 
antagonist. Moreover, the pregnancy rate was 
higher when the antagonist protocol was 
used. What ultimately matters in selecting the 
ovarian stimulation protocol is the outcomes. 
At first glance, the agonist protocol might 
indicate poorer results in this category of 
patients, but the outcomes of the antagonist 
protocol tended to be more satisfactory at the 
end. Similar studies which preferred the 
antagonist protocol in patients with low AMH 
levels indicate treatment costs decline and 
higher patients’ comfort, owing to a reduction 
in gonadotropin dose and canceled cycles. By 
the same token, a broader study has been 
conducted on ovarian stimulation protocol in 
women with low AMH levels. Despite more 
intense stimulation through the agonist 
protocol, there was no difference in the 
number of oocytes, canceled cycles and 
pregnancy rate through the antagonist 
protocol (20).  
Similar to our findings, the previous study 
introduced the antagonist protocol as the front 
line of treatment for people with low AMH 
levels (21). Contrary to our findings, Malmusi 
et al, Sun and Zhu preferred the agonist 
protocol due to a higher number of oocytes 
and embryos in women with low AMH levels 
(22, 23). Regardless of the type of protocol, 
there was a very low pregnancy rate in this 
category of patients. This could be due to 
defects in granulosa cells, which produce the 
AMH as mentioned earlier. The defects in the 
supporting cells decreased the quality of 
oocytes, which in turn led to lower 
implantation and pregnancy in women with 
low AMH levels (24, 25).  
According to our findings, the agonist 
protocol in women with normal AMH levels 
leads to a greater number of oocytes and 
embryos (2). Moreover, the pregnancy rate 
was higher than that in the antagonist protocol 
(26, 27). Some studies have suggested that 
the agonist protocol in patients with normal 
ovarian response is associated with higher 
number of oocytes, implantation and 
pregnancy rates, as well as an increase in live 
births and reduction in canceled cycles (28). A 
few studies prefer the agonist protocol over 
the antagonist protocol in normal respondents 
because of the negative impact of the latter on 
the performance of major endometrial proteins 
(29). In this regard, there have been other 
studies rejecting that statement on the 
grounds that endometrial receptivity in the 
antagonist protocol is similar to the natural 
endometrial cycle (30). According to our 
findings, however, the agonist protocol yielded 
more favorable results in women with normal 
AMH levels and ovarian responses.  
The previous studies have suggested 
mixed results on high levels of serum AMH 
and selecting the type of treatment protocol 
(31). In the selection of agonist protocol for 
ovarian stimulation in patients with high AMH 
levels, Nelson et al and Manno et al reported 
an increase in pregnancy rate. Moreover, it 
was accompanied by an increase in the 
incidence of ovarian hyperstimulation 
syndrome (OHSS) and canceled cycles (17, 
32). In contrast to these results, the molecular 
studies on the oocytes, obtained through the 
antagonist protocol in patients with high AMH 
levels, indicated that the gene expressions of 
ATPase and BMP15, as two indicators of 
oocyte quality, enhanced through the 
antagonist protocol (4). Therefore, the 
antagonist protocol can be the more desirable 
option in high AMH cases. In an analysis, La 
Marca and Sunkara argued that the 
antagonist protocol in patients with high 
ovarian responses curtails the risk of OHSS, 
AMH and ovarian stimulation protocols 
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because the use of antagonist protocol 
depends on the patient’s endocrine conditions 
(14). Hence, it may lead to lower number of 
follicles during ovarian stimulation. Moreover, 
it entails a shorter treatment period and higher 
pregnancy rate than the agonist protocol (33).  
These results are consistent with our 
findings, where the number of high quality 
embryos and pregnancy rates significantly 
increased despite the lower number of 
oocytes obtained by the antagonist protocol. 
Therefore, the antagonist protocol is the more 
suitable option for patients with high serum 
AMH levels. According to a positive 
correlation of AMH levels with the number of 
retrieved oocytes, embryo count and 
pregnancy rate in both different protocols, 
AMH is an adequate predictor of ovarian 
response and ART outcomes. Further AMH-
tailored protocol selection improved ART 
outcomes. These findings are similar to 
Hamdine et al findings (15).  
This retrospective study generally 
demonstrated that the agonist protocol is the 
more suitable option for the normal range of 
serum AMH given the number of oocytes and 
high quality embryos leading to higher 
pregnancy rate. Since low AMH levels provide 
no prognosis for ovarian response and 
pregnancy rate, the selection of a good 
protocol can improve the pregnancy rate in 
patients who barely respond to treatment due 
to excessive ovarian stimulation.  
Hence, the administration of high-dose 
gonadotropin and agonist protocol are not 
associated with improvement of outcomes. It 
is better to select the antagonist as the more 
ideal ovarian stimulation strategy for low AMH 
level given the higher pregnancy rate. Since 
the antagonist protocol in patients with high 
AMH levels leads to greater patient comfort 
and lower risks associated with ovarian hyper-
stimulation and above all, yielding more 
desirable outcomes, it can be regarded as a 
safe technique for ovarian stimulation.  
 
Conclusion 
 
According to these results, it can be 
concluded that the ovarian stimulation 
protocol should be selected based on the 
patient’s’ specific characteristics. Moreover, 
the prediction of ovarian response and 
pregnancy rate can curtail the treatment costs 
and pave the way for successful assisted 
reproductive techniques. 
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